INmune Bio (INMB) to Release Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) will be issuing its quarterly earnings data after the market closes on Thursday, May 9th.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.47) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter. INmune Bio had a negative return on equity of 64.11% and a negative net margin of 19,360.00%.

INmune Bio Stock Performance

INMB stock traded down $0.29 during midday trading on Wednesday, hitting $10.89. 8,707 shares of the stock were exchanged, compared to its average volume of 103,620. INmune Bio has a fifty-two week low of $6.50 and a fifty-two week high of $14.74. The stock’s 50-day moving average price is $11.14 and its 200-day moving average price is $10.65. The stock has a market cap of $198.20 million, a price-to-earnings ratio of -6.69 and a beta of 1.92.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.